These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18853950)

  • 21. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 23. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients.
    Kandula P; Fridell J; Taber TE; Sharfuddin A; Yaqub MS; Phillips CL; Chen J; Mujtaba M
    Transplantation; 2012 Nov; 94(9):940-6. PubMed ID: 23037007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer in kidney transplant recipients - a nationwide register study.
    Bratt O; Drevin L; Prütz KG; Carlsson S; Wennberg L; Stattin P
    BJU Int; 2020 May; 125(5):679-685. PubMed ID: 31955497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.
    Braun F; Schöcklmann H; Ziegler E; Kunzendorf U; Armstrong VW; Renders L
    Clin Pharmacol Ther; 2009 Oct; 86(4):411-5. PubMed ID: 19606088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients.
    Shapiro R; Scantlebury VP; Jordan ML; Vivas CA; Jain A; Hakala TR; McCauley J; Johnston J; Randhawa P; Fedorek S; Gray E; Chesky A; Dvorchik I; Donaldson J; Fung JJ; Starzl TE
    Transplant Proc; 2002 Aug; 34(5):1651-2. PubMed ID: 12176521
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients.
    Russ GR; Campbell S; Chadban S; Eris J; O'Connell P; Pussell B; Walker R;
    Transplant Proc; 2003 May; 35(3 Suppl):115S-117S. PubMed ID: 12742480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal function and histology in kidney transplant patients receiving tacrolimus and sirolimus or mycophenolate mofetil.
    Kamar N; Van TT; Ribes D; Modesto A; Cointault O; Lavayssière L; Ader JL; Durand D; Rostaing L
    Exp Clin Transplant; 2006 Dec; 4(2):532-6. PubMed ID: 17238854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
    Chueh SC; Wang SM; Lai MK; Chen J
    Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
    Tohme FA; Kalil RS; Thomas CP
    Transpl Infect Dis; 2015 Feb; 17(1):66-72. PubMed ID: 25582442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients.
    Gong N; Chen Z; Wang J; Fang A; Li Y; Xiang Y; Ming C; Zhang W
    Cell Immunol; 2015 Oct; 297(2):87-93. PubMed ID: 26205091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure.
    Filler G; Womiloju T; Feber J; Lepage N; Christians U
    Am J Transplant; 2005 Aug; 5(8):2005-10. PubMed ID: 15996252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of Prostate Cancer Screening in Kidney Transplant Candidates.
    Vitiello GA; Sayed BA; Wardenburg M; Perez SD; Keith CG; Canter DJ; Ogan K; Pearson TC; Turgeon N
    J Am Soc Nephrol; 2016 Jul; 27(7):2157-63. PubMed ID: 26701982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.
    Wu FL; Tsai MK; Chen RR; Sun SW; Huang JD; Hu RH; Chen KH; Lee PH
    Pharmacotherapy; 2005 May; 25(5):646-53. PubMed ID: 15899725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.